Proniras focuses on development of a new parenteral medical countermeasure (MCM) to treat seizures and brain injury.
Proniras has raised $4.7M in total funding. The most recent round was Series B. The last funding was announced in February 2024.
Proniras's investors include ARCH Venture Partners, Accelerator Life Science Partners, WRF Capital, Watson Fund.
Proniras is headquartered in Seattle, United States.
Proniras focuses on development of a new parenteral medical countermeasure (MCM) to treat seizures and brain injury.
Proniras is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Proniras — Funding & Investors." VCBacked, February 1, 2024, https://www.vcbacked.co/company/proniras. Accessed September 12, 2026.
VCBacked. (2024). Proniras — Funding & Investors. Retrieved September 12, 2026, from https://www.vcbacked.co/company/proniras
{{cite web |title=Proniras — Funding & Investors |url=https://www.vcbacked.co/company/proniras |website=VCBacked |access-date=September 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated